AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02814604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Rating Systems
Description: Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.
Study NCT01827111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.
Study NCT01827111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
Study NCT03860194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protison with High Protein 51(Original Flavor)
Description: Contents of each supplement sachet has a calorie of 88 kcal, 12.8 g protein( including 8.5 g whey protein concentrate), 1.2 g leucine, 7.3 g carbohydrates, 0.8 g fat and 120 IU vitamin D per serving. This supplement was added 200 ml water and stirred well, then drank before meal.
Study NCT05090072 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advance Directives
Description: The palliative care physician engaged patients and their caregivers in an open discussion about patients' answers to the Advance Directives document, to explore and clarify all doubts and questions prompted by the document
Study NCT05090072 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The palliative care physician undergone a conference with both patients and caregivers and evaluated patients' symptoms using the the Edmonton Frail Scale (Bruera, 1991), adapted to the Portuguese population. The Advance Directives theme wasn't approached during this conference.
Study NCT01827111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
Study NCT03983525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goji berry
Description: Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take 28 grams of goji berry once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
Study NCT03983525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein + zeaxanthin supplementation
Description: Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take one capsule of lutein + zeaxanthin supplementation once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
Study NCT03591848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online support decision tool
Description: Online support decision tool, in addition of the standard oral information
Study NCT03591848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard oral information
Description: standard oral information
Study NCT03591848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard oral information
Description: standard oral information
Study NCT02925962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS)
Description: A targeted, automated CKD clinical decision support system (CDSS) designed to improve bloodpressure (BP) level, disease awareness, staging, processes of care, and knowledge among persons with documented reduced eGFRcreat (creatinine-based estimated glomerular filtration rate) in primary care setting.
Study NCT02925962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinic Decision Sup System + Pharmacist
Description: Includes everything in the CDSS intervention but adds a follow-up call from a pharmacist, who is part of the clinical team. The rationale for this third arm is based on the evidence that clinical pharmacists have been shown to be more effective than physicians alone at achieving BP control in other settings.
Study NCT04153461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MINI-PERCUTANEOUS NEPHROLITHOTOMY
Description: MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
Study NCT06585189 — intervention group
Intervention type: DRUG
Intervention: Cisplatin
Study NCT06585189 — intervention group
Intervention type: DRUG
Intervention: Carboplatin
Study NCT04153461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD PERCUTANEOUS NEPHROLITHOTOMY
Description: PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
Study NCT01531478 — intervention group
Intervention type: OTHER
Intervention: Unique medical visit of the study
Description: The visit will be with an oncologist specialized in the long-term follow-up of cured pediatric cancer patients. The examination will consist in weight and height measurements, a clinical examination and a measurement of arterial pressure. The list of drugs taken in the last two years, as well as all health issues encountered since the cancer treatment, will be collected. Success in education, career and, family status will also be discussed.~After the medical examination, patients will be offered a visit with a psychologist in order to assess their psychopathological outcomes. This questionnaire is a interquestionnaire designed to screen axis I psychopathological conditions. It includes an evaluation of all types of risk-taking behavior (alcohol, drugs, anorexia and bulimia).
Study NCT01536795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR279,396 with Tegaderm Dressing
Description: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
Study NCT01536795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279,396 with Gauze and Tape Dressing
Description: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
Study NCT02549781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Go-Nogo test
Description: In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization.
Study NCT02549781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Go-Nogo test
Description: In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization.
Study NCT02549781 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Go-Nogo test
Description: In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization.
Study NCT01779843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT01779843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Study NCT01779843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Study NCT02445820 — intervention group
Intervention type: DRUG
Intervention: HES
Description: 2500 mL of balanced HES 130/0.4
Study NCT02445820 — intervention group
Intervention type: DRUG
Intervention: Crystalloid
Description: 2500 mL of balanced crystalloid.
Study NCT01665235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
Study NCT01665235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI / ARB
Description: ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
Study NCT01665235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin or Clopidogrel
Description: aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
Study NCT01665235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin or Clopidogrel
Description: aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
Study NCT01665235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10 - 40mg / d ( statin therapy)
Study NCT01665235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10 - 40mg / d ( statin therapy)
Study NCT00171977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Study NCT04915469 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized enhanced adherence counseling package
Description: A standardized package was developed to support the adherence counsellor and other cadres to ensure provision of quality EAC sessions for children, adolescents and their caregivers. The package included; 1) Orientation and on job mentorship on EAC processes to clinicians, nurses, peer educators and mentor mothers. 2) Using a communication's training curriculum, providers were trained on psychosocial support and communication skills for children and their caregivers. 3) Appointment management was done using appointment dairies or a digital platform that sends patients short message services (SMS) reminders 3 days and 1 day before a scheduled clinic day. 4)Home visits. - All home visits were done according to the EGPAF standard operation procedures (SOPs) drawn from the Kenya National guidelines. 5) Individualized case management -Each EAC client was allocated a case manager who ensured that the barriers to adherence were identified and tackled both at individual and community level.
Study NCT01853150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS Motor cortex
Study NCT01853150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS Supplementary motor area
Study NCT00363766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636-sodium
Description: A loading dose to target 420 micrograms/milliliter (µg/mL) maximum concentration (Cmax) or 380 µg/mL Cmax followed by a lower chronic dose to maintain Cmax within these target ranges, intravenous, every 21 days until disease progression.
Study NCT02798198 — intervention group
Intervention type: OTHER
Intervention: T2DM
Description: T2DM without DKD
Study NCT00802334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: generic lopinavir/ritonavir
Description: 1. Screening visit~   • Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available~2. Baseline visit~   • (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician~3. Week 4~   * Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)~Clinical, safety and laboratory assessment~Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment
Study NCT00019682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study NCT03816202 — intervention group
Intervention type: DEVICE
Intervention: Sundt carotid shunt
Description: The Integra Sundt™ carotid shunts are indicated for temporary carotid artery bypass during carotid endarterectomy procedures to help protect the cerebral hemispheres from ischemia during the period of carotid artery occlusion.
Study NCT02241200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aranesp
Study NCT04143997 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A clinical Transthoracic echocardiogram
Description: A previously clinically completed transthoracic echocardiogram will be utilized to assess for diastolic dysfunction in the presence of normal systolic function for patients with previously diagnosed peripartum cardiomyopathy.
Study NCT03576469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor [recombinant] (C1-INH-R)
Description: C1-INH-R is FDA approved and indicated for the treatment of acute attacks of angioedema in adolescent and adult patients with Hereditary Angioedema (HAE) as a replacement for low levels of C1-esterase inhibitor or low function of C1-esterase inhibitor
Study NCT03307902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imiquimod + ID HBVv
Description: Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine
Study NCT03307902 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous + ID HBVv
Description: Aqueous ointment + intradermal 10μg Sci-B-Vac vaccine
Study NCT03307902 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod + IM HBVv
Description: Imiquimod ointment + intramuscular 10μg Sci-B-Vac vaccine
Study NCT01506063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine DiHCl
Description: Levocetirizine DiHCl Tablets 5 mg
Study NCT01506063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine DiHCl
Description: Levocetirizine DiHCl Tablets 5 mg
Study NCT03455114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AssiAnchor
Description: The novel device, the capsular Anchor, was designed to secure the capsular bag to the scleral wall. The device is a one-piece, one-plane intraocular implant . It works like a paper clip; holding the anterior capsule between a central rod, placed in front of the capsule, and the two lateral arms, inserted through the eye surgery and placed behind the capsule.
Study NCT04534088 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss plus Non-Weight-Related VR app
Description: Standard Behavioral Weight Loss Program
Study NCT04534088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Behavioral Weight Loss plus Weight-Related VR app
Description: Standard Behavioral Weight Loss plus Weight-Related VR app
Study NCT00710086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain
Study NCT00710086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
Study NCT00265863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Description: Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
Study NCT03463824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group 1
Description: Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
Study NCT03463824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group 2
Description: Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
Study NCT03904667 — intervention group
Intervention type: OTHER
Intervention: Watson on oncology surgery decision evaluation
Description: Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.
Study NCT01878500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative stereotactic imaging with VectorVision
Description: Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure. Prior to the operation a team consisting of pediatric urologist, pediatric radiologists, and a VectorVision rep will use pre-operative MRI to map out specific bony and muscular structures of the pelvic floor. Doing so will allow the pediatric urologist to use these markers intraoperatively to help guide his closure and also allow for future surgeons who use this technology to understand the correct planes to develop for the same surgery.
Study NCT02007187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danhong injection
Description: A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
Study NCT02007187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association
Study NCT02007187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association
Study NCT02007187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Study NCT01844869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omacetaxine mepesuccinate
Study NCT00019682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 Antigen
Description: Given SC
Study NCT00019682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC
Study NCT00019682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00019682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00019682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00649155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin Extended-Release Tablets 500 mg
Description: 500mg, single dose fasting
Study NCT00649155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipro® XR Tablets (500 mg
Description: 500mg, single dose fasting
Study NCT03858660 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00530452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: Dual-acting COX-2 inhibitor \& carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).
Study NCT00801827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 (fallypride)
Description: Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
Study NCT03384758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Therapy
Description: Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.
Study NCT03384758 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Compression Therapy
Description: Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.